Welcome to LookChem.com Sign In|Join Free
  • or
3-(3',5'-di-tert-butyl-4'-hydroxy-4-biphenyl)octahydropyrido[2,1-c][1,4]oxazin-3-ol hydrobromide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1375263-25-4

Post Buying Request

1375263-25-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1375263-25-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1375263-25-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,5,2,6 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1375263-25:
(9*1)+(8*3)+(7*7)+(6*5)+(5*2)+(4*6)+(3*3)+(2*2)+(1*5)=164
164 % 10 = 4
So 1375263-25-4 is a valid CAS Registry Number.

1375263-25-4Downstream Products

1375263-25-4Relevant academic research and scientific papers

New multifunctional di- tert -butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action

Ladopoulou, Eleni,Matralis, Alexios N.,Kourounakis, Angeliki P.

, p. 3330 - 3338 (2013)

Oxidative stress, inflammation, and hyperlipidemia are common factors involved in the pathophysiology of atherosclerosis and type 2 diabetes. We have previously developed multifunctional antidyslipidemic derivatives with antioxidant and antiatherogenic properties. We now report the design, synthesis, and evaluation of two such novel derivatives that incorporate a structural moiety of the antidiabetic agent succinobucol. The new compounds exhibited a much improved in vitro antioxidant and squalene synthase inhibitory activity (at lower micromolar concentrations) as well as a significant antihyperlipidemic effect, reducing plasma total cholesterol, triglycerides, and MDA by 65-90%. Compound 2 also indicated a good anti-inflammatory activity, decreasing edema by 44%, while it was further evaluated for its antidiabetic activity using a type 2 diabetes experimental mouse model. After 7 weeks of administration, it produced a significant antihyperglycemic and antihyperlipidemic activity. In conclusion, rational drug design led to a compound combining improved antioxidant, antidyslipidemic, and antidiabetic action that may serve as a potential therapeutic strategy in metabolic syndrome disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1375263-25-4